<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03458481</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DDAG181PA-16-005</org_study_id>
    <nct_id>NCT03458481</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Yimitasvir Phosphate Capsules</brief_title>
  <official_title>A Multicenter, Randomized, Parallel Assigned, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and&#xD;
      treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 2, multicenter, randomized, parallel Assigned, open-label study to explore the&#xD;
      safety, tolerability and antiviral activity of DAG181/SOF combination for 12 weeks in adult&#xD;
      subjects with chronic genotype 1 HCV infection.&#xD;
&#xD;
      Approximately 120 HCV genotype 1 subjects without cirrhosis will be enrolled,&#xD;
      treatment-experienced subjects are ≤20%, all subjects will be randomized (1:1) to one of the&#xD;
      following two treatment groups by IWRS (Medidata Balance): a) DAG181 100 mg/ SOF 400 mg once&#xD;
      daily for 12 weeks, b) DAG181 200 mg/ SOF 400 mg once daily for 12 weeks. Randomization will&#xD;
      be stratified by &quot;treatment-naive&quot; or &quot;treatment-experienced&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Actual">September 26, 2018</completion_date>
  <primary_completion_date type="Actual">May 8, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability were evaluated based on adverse event monitoring, laboratory tests, 12-lead ECG assessments, vital signs measurements and physical examinations.</measure>
    <time_frame>Up to posttreatment week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with sustained virologic response 4, 8 and 24 weeks after discontinuation of therapy (SVR4,SVR8 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 4,8 and 24</time_frame>
    <description>SVR4,SVR8 and SVR24 were defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) at 4, 8 and 24 weeks after stopping study treatment, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with HCV RNA &lt; the lower limit of quantitation (LLOQ) while on treatment</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first achieve &quot;HCV RNA &lt; the lower limit of quantitation (LLOQ)&quot; while on treatment</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA change from baseline</measure>
    <time_frame>Up to posttreatment week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with virologic failure</measure>
    <time_frame>Up to posttreatment week 24</time_frame>
    <description>Virologic failure was defined as:&#xD;
On-treatment virologic failure: Breakthrough (confirmed HCV RNA ≥the lower limit of quantitation (LLOQ) after having previously had HCV RNA &lt;the lower limit of quantitation (LLOQ) while on treatment), or Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or Non-response (HCV RNA persistently ≥the lower limit of quantitation (LLOQ) through 8 weeks of treatment);&#xD;
Virologic relapse: Confirmed HCV RNA ≥the lower limit of quantitation (LLOQ) during the posttreatment period having achieved HCV RNA &lt;the lower limit of quantitation (LLOQ) at last on-treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral resistance</measure>
    <time_frame>Up to posttreatment week 24</time_frame>
    <description>Viral resistance to DAG181 and/or SOF during treatment and after cessation of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Chronic HCV Infection</condition>
  <arm_group>
    <arm_group_label>SOF+DAG181 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+DAG181 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF</intervention_name>
    <description>400 mg tablet administered orally once daily</description>
    <arm_group_label>SOF+DAG181 100 mg</arm_group_label>
    <arm_group_label>SOF+DAG181 200 mg</arm_group_label>
    <other_name>sofosbuvir</other_name>
    <other_name>Sovaldi®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAG181</intervention_name>
    <description>Capsule administered orally once daily</description>
    <arm_group_label>SOF+DAG181 100 mg</arm_group_label>
    <arm_group_label>SOF+DAG181 200 mg</arm_group_label>
    <other_name>Yimitasvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent;&#xD;
&#xD;
          2. Male or female, age≥18 years;&#xD;
&#xD;
          3. A female subject is eligible to enter the study if it is confirmed that she is:&#xD;
&#xD;
               1. Of non-childbearing potential (i.e., women who have had a hysterectomy, have both&#xD;
                  ovaries removed or medically documented ovarian failure, or are&#xD;
                  postmenopausal-women &gt; 50 years of age with cessation (for≥12 months) of&#xD;
                  previously occurring menses), or&#xD;
&#xD;
               2. Of childbearing potential (Women≤50 years of age with amenorrhea will be&#xD;
                  considered to be of childbearing potential). These women must have a negative&#xD;
                  serum pregnancy test at screening, and must use specific contraceptive methods&#xD;
                  from screening until 4 weeks after last dose of study drugs, such as complete&#xD;
                  abstinence from intercourse, vaginal ring, cervical cap or contraceptive&#xD;
                  diaphragm, IUD, etc.&#xD;
&#xD;
          4. All male study subjects must agree to consistently and correctly use specific&#xD;
             contraceptive methods with their female partner from screening until 4 weeks after&#xD;
             last dose of study drugs(except of surgical sterilization), such as complete&#xD;
             abstinence from intercourse, condom, and their female partner use contraceptives ,&#xD;
             vaginal ring , cervical cap or contraceptive diaphragm, IUD, etc.&#xD;
&#xD;
          5. Male subjects must agree to refrain from sperm donation from the date of screening&#xD;
             until 4 weeks after the last dose of study drugs;&#xD;
&#xD;
          6. Body mass index (BMI)≥18.0 and≤32.0 kg/m2, and Weight≥40 kg;&#xD;
&#xD;
          7. Confirmation of chronic HCV infection documented by either:&#xD;
&#xD;
               1. A positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping&#xD;
                  test at least 6 months prior to the Baseline/Day 1 visit, or&#xD;
&#xD;
               2. A liver biopsy performed prior to the Baseline/Day 1 visit with evidence of&#xD;
                  chronic HCV infection.&#xD;
&#xD;
          8. Serological detection of anti-HCV antibodies was positive at screening;&#xD;
&#xD;
          9. HCV RNA≥1×104 IU/mL at Screening;&#xD;
&#xD;
         10. HCV genotype 1a, 1b, or mixed 1a/1b at screening as determined by the Central&#xD;
             Laboratory;&#xD;
&#xD;
         11. Classification as treatment naive or treatment experienced:&#xD;
&#xD;
               1. Treatment naive is defined as having never been exposed to approved or&#xD;
                  experimental HCV-specific direct-acting antiviral agents or prior treatment of&#xD;
                  HCV with interferon (with or without ribavirin);&#xD;
&#xD;
               2. Treatment experienced is defined as prior treatment failure to a regimen&#xD;
                  containing interferon (IFN-α,β or Peg-IFN±RBV) that was completed at least 2&#xD;
                  months prior to screening. and the subject's medical records must include&#xD;
                  sufficient detail of prior virologic failure to allow for categorization of prior&#xD;
                  response, as either:&#xD;
&#xD;
             i) Non-Responder: Decrease of HCV RNA&lt;2 log at week 12 compared to baseline; ii)&#xD;
             Partially-Responder: Decrease of HCV RNA&gt;2 log at week 12 compared to baseline, and&#xD;
             detectable HCV RNA levels within week 12 and week 24; iii) Breakthrough/Relapse:&#xD;
             Subject achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) during treatment, but&#xD;
             did not achieve sustained virologic response (SVR); iv) Intolerance: Subjects have&#xD;
             discontinued interferon-based treatment due to intolerance which proved by chief&#xD;
             complaint or medical records.&#xD;
&#xD;
         12. Absence of cirrhosis is defined as any one of the following:&#xD;
&#xD;
               1. Liver biopsy within 2 years of Screening or at Screening showing absence of&#xD;
                  cirrhosis (e.g. Metavir score=0-3 or Ishak score&lt;5), or&#xD;
&#xD;
               2. Fibroscan within 6 months of Screening or at Screening with a result of ≤12.5&#xD;
                  kPa.&#xD;
&#xD;
             liver biopsy results will supersede fibroscan results and be considered definitive.&#xD;
&#xD;
         13. Subject must be able to comply with the dosing instructions for study drug&#xD;
             administration and able to complete the study schedule of assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following exclusion criteria are not to be enrolled in this&#xD;
        study:&#xD;
&#xD;
          1. Current or prior history of any of the following:&#xD;
&#xD;
               1. Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal&#xD;
                  hemorrhage);&#xD;
&#xD;
               2. Chronic liver disease of a non-HCV etiology (Including but not limited to&#xD;
                  hemochromatosis, Wilson's disease,alfa-1 antitrypsin deficiency);&#xD;
&#xD;
               3. Significant cardiac disease(Including but not limited to myocardial infarction,&#xD;
                  bradycardia) ;&#xD;
&#xD;
               4. Significant pulmonary disease;&#xD;
&#xD;
               5. Malabsorption syndrome or gastrointestinal disorder or post operative condition&#xD;
                  that could interfere with the absorption of the study drug;&#xD;
&#xD;
               6. Central nervous system trauma, epilepsy, stroke or transient ischemic attack;&#xD;
&#xD;
               7. Psychiatric illness or psychological disease or relevant medical history;&#xD;
&#xD;
               8. Malignancy diagnosed before signing the informed consent form ( except for&#xD;
                  specific cancers that have been cured by surgical resection (basal cell skin&#xD;
                  cancer, etc) or cervical carcinoma in situ are allowed). subjects under&#xD;
                  evaluation for malignancy are not eligible;&#xD;
&#xD;
               9. Solid organ transplantation;&#xD;
&#xD;
              10. Subjects have any other medical disorder that may interfere with subjects&#xD;
                  treatment, assessment or compliance with the protocol.&#xD;
&#xD;
          2. Subjects has the following laboratory parameters at screening:&#xD;
&#xD;
               1. ALT &gt; 10×the upper limit of normal (ULN);&#xD;
&#xD;
               2. AST &gt; 10×ULN;&#xD;
&#xD;
               3. Total bilirubin&gt; 1.5 × ULN;&#xD;
&#xD;
               4. Albumin&lt; 3.5 g/dL;&#xD;
&#xD;
               5. AFP&gt;100 ng/mL; If 20 ng/mL≤AFP≤100 ng/mL, a liver ultrasound examination is&#xD;
                  required to exclude subjects suspected of hepatocellular carcinoma;&#xD;
&#xD;
               6. INR &gt; 1.5 x ULN;&#xD;
&#xD;
               7. Hemoglobin&lt;11 g/dL for female subjects; &lt;12 g/dL for male subjects;&#xD;
&#xD;
               8. Platelets&lt;90 x109/L;&#xD;
&#xD;
               9. Neutrophil absolute count&lt; 1.5 ×109/L;&#xD;
&#xD;
              10. HbA1c &gt; 8.5%;&#xD;
&#xD;
              11. Creatinine clearance (CLcr) &lt;50 mL /min as calculated by the Cockcroft-Gault&#xD;
                  equation;&#xD;
&#xD;
              12. HBsAg serology test results were positive;&#xD;
&#xD;
              13. HIV antibody test results were positive.&#xD;
&#xD;
          3. Screening ECG with clinically significant abnormalities;&#xD;
&#xD;
          4. Prior exposure to approved or experimental HCV-specific direct-acting antiviral agent;&#xD;
&#xD;
          5. Use of any prohibited concomitant medications;&#xD;
&#xD;
          6. Significant drug allergy, or known hypersensitivity to DAG181, SOF and its&#xD;
             metabolites, or formulation recipients;&#xD;
&#xD;
          7. A positive drug screen at screening will exclude subjects unless it can be explained&#xD;
             by non-prescription drug or prescribed medication; the diagnosis and prescription must&#xD;
             be approved by the investigator;&#xD;
&#xD;
          8. Pregnant or nursing female or male with pregnant female partner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lai Wei, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Tongji Medical College of Huazhong University Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangyan Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of NanChang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Chang Chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 10, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Genotype 1 HCV Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Yimitasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

